FR3112939B1 - Produit universel de thérapie cellulaire et son utilisation - Google Patents

Produit universel de thérapie cellulaire et son utilisation Download PDF

Info

Publication number
FR3112939B1
FR3112939B1 FR2008211A FR2008211A FR3112939B1 FR 3112939 B1 FR3112939 B1 FR 3112939B1 FR 2008211 A FR2008211 A FR 2008211A FR 2008211 A FR2008211 A FR 2008211A FR 3112939 B1 FR3112939 B1 FR 3112939B1
Authority
FR
France
Prior art keywords
cell therapy
cell
therapy product
universal cell
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR2008211A
Other languages
English (en)
French (fr)
Other versions
FR3112939A1 (fr
Inventor
Martin Villalba
Christian Jorgensen
Bruno Robert
Pierre Martineau
Francisco Javier Hernandez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Montpellier
Original Assignee
University of Montpellier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR2008211A priority Critical patent/FR3112939B1/fr
Application filed by University of Montpellier filed Critical University of Montpellier
Priority to EP21758336.8A priority patent/EP4188396A1/en
Priority to CA3189963A priority patent/CA3189963A1/en
Priority to CN202180067847.XA priority patent/CN116744946A/zh
Priority to US18/018,687 priority patent/US20240293455A1/en
Priority to JP2023507231A priority patent/JP2023535842A/ja
Priority to PCT/EP2021/071586 priority patent/WO2022023581A1/en
Priority to KR1020237007319A priority patent/KR20230078632A/ko
Priority to AU2021316729A priority patent/AU2021316729A1/en
Publication of FR3112939A1 publication Critical patent/FR3112939A1/fr
Application granted granted Critical
Publication of FR3112939B1 publication Critical patent/FR3112939B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
FR2008211A 2020-07-31 2020-07-31 Produit universel de thérapie cellulaire et son utilisation Active FR3112939B1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
FR2008211A FR3112939B1 (fr) 2020-07-31 2020-07-31 Produit universel de thérapie cellulaire et son utilisation
CA3189963A CA3189963A1 (en) 2020-07-31 2021-08-02 Universal cell therapy product and use thereof
CN202180067847.XA CN116744946A (zh) 2020-07-31 2021-08-02 用于通用细胞疗法的武装nk细胞
US18/018,687 US20240293455A1 (en) 2020-07-31 2021-08-02 Armed nk cells for universal cell therapy
EP21758336.8A EP4188396A1 (en) 2020-07-31 2021-08-02 Armed nk cells for universal cell therapy
JP2023507231A JP2023535842A (ja) 2020-07-31 2021-08-02 普遍的な細胞療法のための武装ｎｋ細胞
PCT/EP2021/071586 WO2022023581A1 (en) 2020-07-31 2021-08-02 Armed nk cells for universal cell therapy
KR1020237007319A KR20230078632A (ko) 2020-07-31 2021-08-02 범용 세포 치료를 위한 무장된 nk 세포
AU2021316729A AU2021316729A1 (en) 2020-07-31 2021-08-02 Armed NK cells for universal cell therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2008211A FR3112939B1 (fr) 2020-07-31 2020-07-31 Produit universel de thérapie cellulaire et son utilisation
FR2008211 2020-07-31

Publications (2)

Publication Number Publication Date
FR3112939A1 FR3112939A1 (fr) 2022-02-04
FR3112939B1 true FR3112939B1 (fr) 2024-01-05

Family

ID=74095859

Family Applications (1)

Application Number Title Priority Date Filing Date
FR2008211A Active FR3112939B1 (fr) 2020-07-31 2020-07-31 Produit universel de thérapie cellulaire et son utilisation

Country Status (9)

Country Link
US (1) US20240293455A1 (enExample)
EP (1) EP4188396A1 (enExample)
JP (1) JP2023535842A (enExample)
KR (1) KR20230078632A (enExample)
CN (1) CN116744946A (enExample)
AU (1) AU2021316729A1 (enExample)
CA (1) CA3189963A1 (enExample)
FR (1) FR3112939B1 (enExample)
WO (1) WO2022023581A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115521913B (zh) * 2022-02-22 2023-07-25 北京景达生物科技有限公司 NK细胞与CD20、CD38、Her2抗体联合应用
EP4729126A1 (en) 2024-10-17 2026-04-22 Centre National de la Recherche Scientifique Nk cell-derived extracellular vesicles armed with modified monoclonal antibodies to target cancer cells, and use thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US64413A (en) 1867-05-07 Improvement in wagon-beake
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
AU1908395A (en) 1994-01-28 1995-08-15 Board Of Trustees Of The Leland Stanford Junior University Antibodies to mammalian natural killer antigens and uses
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
FR2915398B1 (fr) * 2007-04-25 2012-12-28 Lab Francais Du Fractionnement "ensemble de moyens pour le traitement d'une pathologie maligne, d'une maladie auto-immune ou d'une maladie infectieuse"
JP2010220479A (ja) * 2007-06-15 2010-10-07 Medeinetto:Kk Ｎｋ細胞の培養方法及びｎｋ細胞の利用
CA2943299A1 (en) * 2014-04-11 2015-10-15 Medimmune, Llc Bispecific her2 antibodies
US20180244787A1 (en) * 2016-12-22 2018-08-30 Sanofi Anti-human cxcr3 antibodies for treatment of vitiligo
CA3052446A1 (en) * 2017-02-02 2018-08-09 The Scripps Research Institute Engineered cells and methods of use

Also Published As

Publication number Publication date
FR3112939A1 (fr) 2022-02-04
KR20230078632A (ko) 2023-06-02
CA3189963A1 (en) 2022-02-03
US20240293455A1 (en) 2024-09-05
CN116744946A (zh) 2023-09-12
AU2021316729A1 (en) 2023-03-02
EP4188396A1 (en) 2023-06-07
WO2022023581A1 (en) 2022-02-03
JP2023535842A (ja) 2023-08-21

Similar Documents

Publication Publication Date Title
Quan et al. The development of novel therapies for rheumatoid arthritis
Hussain et al. Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degeneration
Hussain et al. Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease
Vart et al. Estimated lifetime benefit of combined RAAS and SGLT2 inhibitor therapy in patients with albuminuric CKD without diabetes
Hussain et al. Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy
Andoniou et al. The Cbl proto-oncogene product negatively regulates the Src-family tyrosine kinase Fyn by enhancing its degradation
Treon et al. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenström macroglobulinemia
Reiss et al. Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promising new anticancer strategy
Zarbin Anti-VEGF agents and the risk of arteriothrombotic events
Triantafylla et al. Ranibizumab for the treatment of degenerative ocular conditions
Kawaguchi et al. Efficacy of IDegLira versus IDegAsp therapy in patients with type 2 diabetes: a randomized crossover study by isCGM
Huang et al. Fas and its ligand, caspases, and bcl-2 expression in gonadotropin-releasing hormone agonist-treated uterine leiomyoma
Perrone et al. Targeting inflammation in endometriosis: emerging therapeutic options
Joshi et al. The FLT3N701K mutation causes clinical AML resistance to gilteritinib and triggers TKI sensitivity switch to quizartinib
Mizuno et al. A case of papuloerythroderma successfully treated with dupilumab
Kim et al. Early recurrent hemorrhage in submacular hemorrhage secondary to type 3 neovascularization or retinal angiomatous proliferation: incidence and influence on visual prognosis
Hooks et al. Cellular deficiency in the RGS10 protein facilitates chemoresistant ovarian cancer
Gadducci et al. Progestagen component in combined hormone replacement therapy in postmenopausal women and breast cancer risk: a debated clinical issue
Kato et al. A case report of a truncated ABL1 mutation in 2 cases with Philadelphia chromosome-positive B cell precursor acute lymphoblastic leukemia
Bertelmann et al. Intravitreal functional plasminogen in eyes with branch retinal vein occlusion
Harbeck et al. Neratinib as extended adjuvant treatment of HER2-positive/HR-positive early breast cancer patients in Germany, Austria, and Switzerland: interim results of the prospective, observational ELEANOR study
Javitt et al. Advantages and disadvantages of using Rho kinase inhibitors to reduce intraocular pressure
Kato et al. Intravitreal ranibizumab for patients with neovascular age-related macular degeneration with good baseline visual acuity
Arai et al. Tissue plasminogen activator as an antiangiogenic agent in experimental corneal neovascularization in rabbits
Onsun et al. Comparison of survival and retention rates between infliximab and adalimumab for psoriasis: 10-year experience at a single tertiary center

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20220204

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6